Stay updated with breaking news from Admission Document. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Study met primary endpoint and demonstrated highly significant reductions in Lp to week 36 Lipoprotein reduction was consistent with phase 1 results Topline 48-week data expected in 2Q 2024 ...
Silence also announced positive topline 36-week data from ongoing phase 2 study of zerlasiran in patients with high lipoprotein Company to host conference call and webcast today at 8 a.m. EDT / 12...
Investegate announcements from Proposed Fundraise
Silence Therapeutics plc, Nasdaq: SLN , an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines,...
Investegate announcements from Response to press speculation